Context Therapeutics Inc.
CNTX
$1.52
-$0.19-11.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.01% | 8.64% | 8.67% | 11.35% | 6.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.58% | 32.68% | -7.18% | 91.25% | 42.29% |
| Operating Income | -37.58% | -32.68% | 7.18% | -91.25% | -42.29% |
| Income Before Tax | -45.57% | -35.17% | 12.31% | -84.24% | -29.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.57% | -35.17% | 12.31% | -84.24% | -29.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.57% | -35.17% | 12.31% | -84.24% | -29.60% |
| EBIT | -37.58% | -32.68% | 7.18% | -91.25% | -42.29% |
| EBITDA | -37.58% | -32.67% | 7.20% | -91.28% | -42.30% |
| EPS Basic | -21.83% | 28.20% | 68.91% | 62.50% | 74.03% |
| Normalized Basic EPS | -21.82% | 28.19% | 68.90% | 62.48% | 74.03% |
| EPS Diluted | -21.16% | 27.84% | 68.70% | 62.32% | 73.89% |
| Normalized Diluted EPS | -21.82% | 28.19% | 68.90% | 62.48% | 74.03% |
| Average Basic Shares Outstanding | 21.81% | 63.17% | 119.56% | 242.99% | 389.41% |
| Average Diluted Shares Outstanding | 21.81% | 63.17% | 119.56% | 242.99% | 389.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |